CJC-1295 vs Sermorelin

Side-by-side comparison of CJC-1295, Sermorelin — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute CJC-1295 CJC-1295 (Modified GRF 1-29) Growth Hormone Sermorelin Sermorelin Acetate (GHRH 1-29) Growth Hormone
Basics
Molecular type GHRH AnalogueGHRH Analogue
Amino acids 2929
Molecular weight 3,368.9 Da3,357.9 Da
Half-life 30 min (without DAC) / 7–8 days (with DAC)~10–20 min
Route(s) Subcutaneous, IntramuscularSubcutaneous, IV (diagnostic only)
Mechanism & Research
Primary mechanism CJC-1295 binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and increasing GH pulse amplitude. Unlike native GHRH (half-life <10 minutes), the modified amino acid substitutions in CJC-1295 resi… Sermorelin binds GHRH receptors in the anterior pituitary with similar affinity to native GHRH and stimulates GH synthesis and secretion. Its mechanism is essentially identical to endogenous GHRH — it is distinguished pr…
Research status Research Compound Research Compound
Evidence summary Phase 1/2 trials with CJC-1295 with DAC confirmed dose-dependent IGF-1 elevation lasting up to 14 days after single injection. CJC-1295 without DAC's pulsatile profile is primarily studied in combination with GHRPs. Sermorelin has more human clinical data than any other GHRH analogue due to its period of FDA approval. Adult studies have examined it for age-related GH decline, body composition, and sleep quality.
Protocol & Dosing
Typical dose 100–200 mcg (without DAC); 2mg every 2 weeks (with DAC)200–500 mcg
Frequency 2–3x daily (without DAC); biweekly (with DAC)Once daily at bedtime
Duration 8–16 weeks3–6 months
Timing Without DAC: fasted, 2x daily ideally morning + bedtime. With DAC: any time, biweekly.Bedtime (maximises nocturnal GH pulse)
Safety
Common side effects
  • Water retention
  • Mild headache
  • Flushing (post-injection)
  • Tingling
  • Injection site pain/redness
  • Flushing
  • Headache
  • Dizziness (rare)
Contraindications
  • Active malignancy
  • Uncontrolled hypothyroidism
  • Pregnancy
  • Active malignancy
  • Hypothyroidism (treat first)
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides Ipamorelin, Sermorelin, GHRP-2, Tesamorelin CJC-1295, Ipamorelin, Tesamorelin
Full profile Read full CJC-1295 profile → Read full Sermorelin profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.